Drug Profile
Research programme: embryonic tissue xenotransplants - Tissera
Latest Information Update: 07 Apr 2014
Price :
$50
*
At a glance
- Originator Weizmann Institute of Science
- Developer Tissera
- Class Cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Renal failure; Type 1 diabetes mellitus